AbbVie Inc (ABBV)vsMasimo Corporation (MASI)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
MASI
Masimo Corporation
$178.46
-0.03%
HEALTHCARE · Cap: $9.34B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3906% more annual revenue ($61.16B vs $1.53B). ABBV leads profitability with a 6.9% profit margin vs -9.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MASI
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+14.3%
Fair Value
$157.54
Current Price
$178.46
$20.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 214.4% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 12.9x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MASI
The strongest argument for MASI centers on EPS Growth, Return on Equity. Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MASI
The primary concerns for MASI are Price/Book, PEG Ratio, P/E Ratio. A P/E of 46.5x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while MASI is a turnaround play — different risk/reward profiles.
MASI carries more volatility with a beta of 1.20 — expect wider price swings.
MASI is growing revenue faster at 12.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Masimo Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Masimo Corporation develops, manufactures and markets non-invasive monitoring technologies and hospital automation solutions globally. The company is headquartered in Irvine, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?